Quote this publication Share Print


Opinions on drugs - Posted on Nov 05 2014

Reason for request

Extension of indication


Clinical Benefit



Clinical Added Value

no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).

Contact Us

Évaluation des médicaments
All our publications